|

Cyclophosphamid Clinical Trials

6 actively recruiting trials across 1 location

No change since May 2026

Also known as: CTX, PTCy

Pipeline

Phase 2: 2Phase 1/2: 3Phase 2/3: 1

Top Sponsors

  • Essen Biotech2
  • University of Liege1
  • Second Affiliated Hospital, School of Medicine, Zhejiang University1
  • Masonic Cancer Center, University of Minnesota1
  • Curacell Holding AB1

Indications

Other5 trials

A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC
Phase 1/2
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning
Phase 2
Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer
Phase 2/3
TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer
Phase 1/2
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer
Phase 1/2

Minneapolis, Minnesota1 trial

MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

Masonic Cancer Center at University of Minnesota

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.